Symbols / CBAY
CBAY Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | — | 52W Low | — |
| Beta | — | Avg Volume | — | Volume | — |
| Target Price | — | Recom | — | Prev Close | — |
| Price | — | Change | — |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
- CymaBay (CBAY) Stock Up on Positive Results From PBC Study - Nasdaq Fri, 08 Sep 2023 07
- Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain - Yahoo Finance Mon, 11 Mar 2024 07
- Why is CymaBay (CBAY) Stock Up 25% Today? - InvestorPlace Mon, 12 Feb 2024 08
- CymaBay Therapeutics (CBAY) Stock Price, News & Analysis - MarketBeat ue, 16 Jun 2015 10
- Circling Back On CymaBay Therapeutics (NASDAQ:CBAY) - Seeking Alpha Sun, 19 Nov 2023 08
- Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today - The Motley Fool Mon, 23 Oct 2023 07
- CymaBay's Remarkable Journey - From $5 To $32 In Just Over A Year - RTTNews Mon, 12 Feb 2024 08
- CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire Mon, 11 Sep 2023 07
- Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion - Investopedia Mon, 12 Feb 2024 08
- Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline - Yahoo Finance ue, 13 Feb 2024 08
- CymaBay (NASDAQ:CBAY) Rises on Promising Phase 3 Results in Liver Disease - TipRanks hu, 07 Sep 2023 07
- Valmont Industries director Mogens C. Bay sells $6.98 million in stock - Investing.com ue, 03 Dec 2024 08
- CymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver Franchise (GILD) - Seeking Alpha ue, 13 Feb 2024 08
- Why CymaBay Therapeutics Stock Nose-Dived This Week - The Motley Fool Fri, 19 May 2023 07
- Billionaire Joseph Edelman Snaps Up These 2 Biotech Stocks — Here’s Why You Should Follow - TipRanks Wed, 26 Apr 2023 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CBAY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|